Dawnrays Pharmaceutical (Holdings) Limited
http://www.dawnrays.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dawnrays Pharmaceutical (Holdings) Limited
Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
Innovent Bags China’s First Homegrown PCSK9 Inhibitor Approval
Sintbilo (tafolecimab) is the first among four late-stage domestically developed PCSK9 Inhibitors to win the nod from China’s drug regulator. Despite lack of public reimbursement coverage, the drug could potentially unseat same-class rivals from Amgen and Sanofi/Regeneron.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice